The effect of saralasin (1sar-8-ala-angiotensin II) on blood pressure in patients with Cushing's syndrome.
To investigate the role of the renin angiotensin system in the pathogenesis of hypertension in Cushing's syndrome two patients with hypercorticism were infused with 20 mg saralasin (1-sar-8-ala-angiotensin II) over a period of 30 minutes under constant blood pressue control. In addition, one patient with primary aldosteronism, an established form of mineralocorticoid hypertension, served as control. Neither in the two patients with Cushing's syndrome nor in the patient with primary aldosteronism could a blood pressure lowering effect of saralasin be observed. In the two patients with hypercoritcism both renin activity and plasma aldosterone increased during saralasin infusion. The patient with primary aldosteronism only showed a weak increase in plasma aldosterone concentration.
D000450:Aldosterone / Q000097:blood; D000804:Angiotensin II / Q000031:analogs & derivatives*; D001794:Blood Pressure / Q000187:drug effects*; D003480:Cushing Syndrome / Q000097:blood / Q000150:complications / Q000503:physiopathology*; D005260:Female; D006801:Humans; D006929:Hyperaldosteronism / Q000503:physiopathology; D006973:Hypertension / Q000209:etiology; D012083:Renin / Q000097:blood; D012504:Saralasin / Q000494:pharmacology*
D000804:Angiotensin II; D000450:Aldosterone; D012083:Renin; D012504:Saralasin